Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study.

Autor: Van Gaal LF (AUTHOR), Rissanen AM (AUTHOR), Scheen AJ (AUTHOR), Ziegler O (AUTHOR), Rössner S (AUTHOR), RIO (Rimonabant In Obesity)-Europe Study Group (CORPORATE AUTHOR), Van Gaal, Luc F¹ (AUTHOR), Rissanen, Aila M (AUTHOR), Scheen, André J (AUTHOR), Ziegler, Olivier (AUTHOR), Rössner, Stephan (AUTHOR), RIO-Europe Study Group (CORPORATE AUTHOR)

Publikováno v: Lancet. 4/16/2005, Vol. 365 Issue 9468, p1389-1397. 9p.